Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies.
Adult
Aged
Aged, 80 and over
Anus Neoplasms
/ diagnostic imaging
Cohort Studies
Female
Fluorodeoxyglucose F18
Humans
Lymph Nodes
/ diagnostic imaging
Lymphatic Metastasis
Male
Middle Aged
Positron Emission Tomography Computed Tomography
/ methods
Radiopharmaceuticals
Retrospective Studies
Vaginal Neoplasms
/ diagnostic imaging
Vulvar Neoplasms
/ diagnostic imaging
lymph nodes
radiation
vulvar and vaginal cancer
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
07
03
2020
revised:
26
04
2020
accepted:
12
05
2020
pubmed:
4
6
2020
medline:
29
9
2021
entrez:
4
6
2020
Statut:
ppublish
Résumé
Metastatic involvement of groin nodes can alter radiation therapy planning for pelvic tumors. We retrospectively identified patients with vulvar, vaginal, or anal cancers who underwent Of 55 patients identified for analysis, 75 groins had pathologic evaluation resulting in 75 index groin nodes for analysis with 35 groins pathologically positive for malignancy. Logistic regression identified mean standardized-uptake-value (50% threshold) and short-axis length as the most predictive imaging metrics for metastatic nodal involvement. The probabilistic model performed better at predicting pathologic involvement compared with standard clinical interpretation on analysis (AUC 0.91, 95% CI 0.84 to 0.97 vs 0.80, 95% CI 0.71 to 0.89; p<0.01). Accuracy of
Identifiants
pubmed: 32487684
pii: ijgc-2020-001363
doi: 10.1136/ijgc-2020-001363
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
947-953Informations de copyright
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: BAS has no relevant disclosures to this work, but reports serving in a consultant role for Curium Pharma, ImagingAB, Inc, and Progenics Pharmaceuticals, Inc, serving as advisory board member for GE Healthcare, and his spouse has received lecture honoraria from Siemens. DGM has no relevant disclosures to this work but reports speaking for Clovis and AstraZeneca. MAP has no relevant disclosures to this work but does report relationship with Merck, AstraZeneca, Tesaro, and Clovis Oncology. SM has no relevant disclosures but is supported by NIH K08 CA237822. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.